NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis $74.59 -0.86 (-1.14%) (As of 11/29/2024 05:14 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Incyte Stock (NASDAQ:INCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Incyte alerts:Sign Up Key Stats Today's Range$74.22▼$76.0850-Day Range$63.22▼$83.3852-Week Range$50.35▼$83.95Volume797,636 shsAverage Volume2.59 million shsMarket Capitalization$14.37 billionP/E Ratio532.82Dividend YieldN/APrice Target$77.16Consensus RatingHold Company OverviewIncyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Read More… Urgent Briefing: Why Wyoming is vital for a 2025 AI portfolio (Ad)We have a truly special way for you to gain access to all this information. For one day only … this Black Friday (Cyber Monday) … we are offering an opportunity to score access to this wealth of information … for just $19.You read that correctly — just $19. This offer is limited to Black Friday (Cyber Monday) ONLY Incyte Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks92nd Percentile Overall ScoreINCY MarketRank™: Incyte scored higher than 92% of companies evaluated by MarketBeat, and ranked 130th out of 964 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 9 buy ratings, 11 hold ratings, and 1 sell rating.Amount of Analyst CoverageIncyte has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth1,197.50% Earnings GrowthEarnings for Incyte are expected to grow by 1,197.50% in the coming year, from $0.40 to $5.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 532.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 106.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 532.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 68.26.Price to Earnings Growth RatioIncyte has a PEG Ratio of 8.60. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Incyte's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.69% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently decreased by 5.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.62 Percentage of Shares Shorted3.69% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently decreased by 5.66%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.78 News SentimentIncyte has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Incyte this week, compared to 11 articles on an average week.Search Interest4 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows8 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $856,166.00 in company stock.Percentage Held by Insiders17.60% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Stock News HeadlinesIncyte Co. (NASDAQ:INCY) EVP Sells $293,222.40 in StockNovember 9, 2024 | insidertrades.comIncyte (NASDAQ:INCY) Stock Rating Upgraded by StockNews.comNovember 30 at 1:57 AM | americanbankingnews.comURGENT: Black Friday Flash Sale! (95% Off)For the first time this year, we're allowing you to unlock a lifetime subscription to Behind the Markets and receive 6 exclusive reports at the biggest discount we've ever given. In the past year, Behind the Markets subscribers saw an average of 57.54% in returns.December 1, 2024 | Behind the Markets (Ad)Analysts Set Incyte Co. (NASDAQ:INCY) Price Target at $77.16November 29 at 5:23 AM | americanbankingnews.comAdvocating for the BMT Community, Mia Hamm Issues Powerful Statement on Graft-Versus-Host Disease, Partners With Incyte [EXCLUSIVE]November 28 at 3:41 AM | msn.comIncyte Announces Updated Presentation Time for Upcoming Investor ConferenceNovember 26, 2024 | businesswire.comIncyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual MeetingNovember 25, 2024 | businesswire.comGoldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor StockNovember 23, 2024 | finance.yahoo.comSee More Headlines INCY Stock Analysis - Frequently Asked Questions How have INCY shares performed this year? Incyte's stock was trading at $62.79 at the start of the year. Since then, INCY shares have increased by 18.8% and is now trading at $74.59. View the best growth stocks for 2024 here. How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Tuesday, October, 29th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.19 by $0.12. The company's revenue was up 23.8% compared to the same quarter last year. Read the conference call transcript. Who are Incyte's major shareholders? Incyte's top institutional shareholders include Baker BROS. Advisors LP (15.96%), State Street Corp (5.48%), Geode Capital Management LLC (2.04%) and Point72 Asset Management L.P. (1.23%). Insiders that own company stock include Steven H Stein, Maria E Pasquale, Barry P Flannelly, Vijay K Iyengar, Jonathan Elliott Dickinson, Thomas Tray, Bros Advisors Lp Baker, Wendy L Dixon and Paula J Swain. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings10/29/2024Today12/01/2024Next Earnings (Confirmed)12/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CUSIP45337C10 CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,524Year Founded1991Price Target and Rating Average Stock Price Target$77.16 High Stock Price Target$97.00 Low Stock Price Target$52.00 Potential Upside/Downside+3.4%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$0.14 Trailing P/E Ratio532.82 Forward P/E Ratio186.48 P/E Growth8.6Net Income$597.60 million Net Margins0.80% Pretax Margin6.72% Return on Equity-0.63% Return on Assets-0.45% Debt Debt-to-Equity Ratio0.01 Current Ratio1.87 Quick Ratio1.82 Sales & Book Value Annual Sales$3.70 billion Price / Sales3.89 Cash Flow$2.44 per share Price / Cash Flow30.63 Book Value$16.46 per share Price / Book4.53Miscellaneous Outstanding Shares192,650,000Free Float158,744,000Market Cap$14.37 billion OptionableOptionable Beta0.71 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:INCY) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | Sponsored***TODAY ONLY*** Is this Trump’s Favorite Coin?Donald Trump just emphatically became America's first crypto president. Trump plans to make America, "the...Weiss Ratings | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INCY Stock Alerts